Category Archives: Regenerative Medicine

DUESSELDORF, Germany--(BUSINESS WIRE)--The kick-off for the first SmartMed network meeting (digital) took place on Thursday, October 14th. Almost all network partners were able to attend the 2.5-hour event and exchanged ideas on current and potential projects. The focus here was on getting to know each other as well as targeted networking. With the help of a modern network platform, the participants were encouraged to exchange ideas in virtual chat rooms about the topics of digitization and artificial intelligence, new materials for restoring or healing tissue and organs and new approaches to stem cell therapy.

The next network meeting is planned for the beginning of December 2021. The network partners largely determine the focus of the next meeting themselves; Depending on requirements, either a cross-network workshop or a lecture on a specific topic from the field of regenerative medicine is prepared.

About SmartMed:The international ZIM cooperation network "Regenerative Solutions for Tomorrow's Therapy" is funded by the Federal Ministry for Economic Affairs and Energy as part of the ZIM program (Central Innovation Program for SMEs). The network management of Silversky LifeSciences GmbH launched the association with technological competencies from blockchain to the regulation of medical devices at the beginning of July 2021. Networking is coordinated by Silversky LifeSciences with its business start-up experts with a technology focus in LifeSciences and with extensive experience in the financing, operation, and development of innovative small and medium-sized companies in this sector. "Each partner brings a certain specialist knowledge and thus a unique contribution to the value chain into the network", describes Dr. Mirko Stange, founder, and CEO of Silversky LifeSciences, the win-win situation for everyone involved.

The international focus is on UK, which also offers German network partners a good opportunity to react to the new framework conditions, especially after Brexit and the associated reorganization of international cooperation. The project is supported by the international network management team Maria Fenner, Lena Ehrenpreis and Jessica Stolzenberg. "The aim of the network is to network companies with R&D institutions in order to initiate a lively innovation policy, to promote startups and to promote the exchange and cooperation of regenerative medicine with related industries", says Jessica Stolzenberg. We want to give all SMEs and startups in the industry the opportunity to expand their network and find new cooperation partners. If there is still funding for my own research activities, I don't know who would turn it down, says Lena Ehrenpreis. Maria Fenner adds: Our focus is on the entire field of regenerative medicine and the development of innovative, regenerative therapies, which are based on the latest scientific findings and use the most modern technologies. The focus is on restoring the healthy and functional original state of the affected tissue / organ by linking modern therapeutic approaches, new and functional materials, as well as the use of digital and intelligent systems in the form of algorithms, deep learning and AI. "

The support provided by the network includes advice and practical help with the market launch, applying for grants, close collaboration between experts in order to research or optimize new therapy methods and to bring products to market maturity. All interested parties are cordially invited to contact the network managers to join the discussion, make contacts and start exciting projects.

Read more from the original source:
International ZIM Network: SmartMed - Regenerative Solutions for the Therapies of Tomorrow - Business Wire

Orthocells CelGro platform forms the basis of a specialised collagen rope that could help reconstruct the anterior cruciate ligament, a strong band of tissue linking the thigh and shin bones that can rupture during athletic activity.

() is ready to make waves in the regenerative medicine space with a well-diversified portfolio of drugs at its disposal, according to Pitt Street Researchs Stocks Down Under newsletter.

The companys portfolio includes CelGro for soft tissue repair and dental bone regeneration, Ortho-ATI for tendon regeneration and Ortho-ACI for cartilage regeneration.

Pitt Street believes that as Orthocell continues to further research and trial its therapies, it will be able to address a much larger portion of the market.

The following is an extract from the Stocks Down Under newsletter:

Orthocell listed on the ASX in 2014 and initially had two main products: Ortho-ATI and Ortho-CTI. OrthoATI was the companys lead product for tendon regeneration, with Ortho-CTI being developed for cartilage regeneration. Lastly, the company was in late-stage development for its tissue regeneration technology, called CelGro, with initial human trials underway.

Cartilage tissue is the main connective tissue in the human body and is widely found in joints and bones. Ortho-CTI uses healthy cartilage cells (by extracting healthy articular cartilage from the patient through surgery) and uses it to grow healthy tissue over five weeks. These cells are then deployed into the joint through surgery, where they begin to generate new cartilage, hopefully resulting in complete recovery of the joints over 6-9 months.

Ortho-ATI, on the other hand, is used to treat damaged tendons. It makes use of healthy tendons (using a sample extracted through a biopsy) to cultivate tendon cells in a lab. These cells are then injected into the affected tendon around 4-5 weeks after the biopsy using ultrasound guidance. By late 2015, Ortho-ATI was being used commercially and had already been used to treat over 300 patients.

Ortho-CTI also saw sporadic use in Australia and Southeast Asia. The company was granted patents in numerous jurisdictions, including the US, Australia and Hong Kong, for its various products during this time and continued to expand its clinical presence across Asia. In November 2015, Ortho-CTI was used for the first time on a patient in Singapore.

Despite having access to early commercial opportunities, Orthocell continued to commission clinical trials for Ortho-ATI, mainly to determine its effectiveness against alternatives, such as surgery. One such trial began in July 2016, with results showing that Ortho-ATI was less invasive than traditional treatments (e.g., cortisol injections and physiotherapy) and showed significantly better results.

By the end of 2016, CelGro had also performed extremely well in early-stage clinical trials. It had shown safety and tolerability for being used as a barrier membrane to allow bone growth in dental applications and to treat full-thickness tendon tears.

November 2017 was a pivotal month for the company. Not only did Orthocell treat its 1,000th patient, but it also received CE Mark for CelGro. CE Mark is regulatory approval that allows the specified drug to be sold and marketed in the European Union. CelGro was used for the first time within the EU in May 2018.

Prior to that, in October 2016, the company received approval for a human nerve regeneration study using CelGro. The first results were published in May 2019, showing an 83% improvement in muscle power, which indicated that CelGro could be used to support nerve regeneration.

CelGro further showed an 89% success rate in tendon regeneration and a 96% success rate in nerve repairs in quadriplegic patients in later studies. All these successful studies and the various use-cases for CelGro implied a potential addressable market of over US$2bn, which leads us to believe that Orthocell is not going to find it difficult to grow its business worldwide once approvals are in place.

In December 2020, Orthocell received market approval for CelGro in Australia for dental bone and tissue regeneration. Shortly after, the company received FDA 510(k) clearance, allowing Orthocell to market and supply CelGro in the US.

As of now, CelGro has only obtained approval for a small percentage of its total use cases. We believe that as Orthocell continues to further research and trial its therapies, it will be able to address a much larger portion of the market.

The company is currently busy securing patents for CelGro in multiple jurisdictions. On top of that, Ortho-ATI and CTI continue to show extremely positive results when compared to traditional regenerative treatments.

We believe that Orthocell will continue to go from strength to strength as it further expands its operations and offers its treatments to more patients. This is evident in the companys financial performance as revenue increased 21% in 1HY21 ($446,201) over the corresponding period and other revenues increased by 500% ($228,664). With over $17m in cash at the end of 1HY21, the company has financial runway for the two to three years. By that time, we believe Orthocell should be able to become profitable.

Keeping all these factors in mind, we think Orthocell is a four-star opportunity. While already having numerous products out in the market, we believe the company can leverage its current technology to address many other unmet needs in the regenerative medicine space. We expect Orthocell to continue to seek approval for other use-cases, such as nerve regeneration, vastly expanding its addressable market in the years to come.

Original post:
Orthocell is ready to make waves in the regenerative medicine space: Pitt Street Research - Proactive Investors Australia

Amniotic Products Market: Overview

The amniotic products market is estimated to observe considerable growth during the forecast period of 2021-2031. The growing incidence of burn injuries among a considerable chunk of the global populace coupled with an increase in the awareness programs will assure steady growth for the amniotic products market.

The growing number of traumatic wounds and the rise in ophthalmology, orthopedic, and cosmetic surgeries will have a profound impact on the growth of the amniotic products market. Amniotic-derived products are a subtype of orthobiologic, examined as a latent treatment option through amplification of joint inflammation and healing. The heightening use of these products in several healing applications will present a plethora of growth opportunities for the global market.

Read Report Overview - https://www.transparencymarketresearch.com/amniotic-products-market.html

The use of amniotic products has evolved considerably over the years. The growing use of amniotic membranes for a plethora of conditions related to ophthalmology such as retinal detachments, corneal surface lesions, and limbal stem cell generation will invite exponential growth for the amniotic products market. Furthermore, the research into amniotic products has increased extensively over the years, especially across orthopedics. Hence, these factors will have a profound impact on the growth of the amniotic products market.

Transparency Market Research (TMR) has obtained considerable information on the overall growth trajectory of the amniotic products market. The upcoming report on the amniotic products market gives a detailed insight about diverse growth aspects. Furthermore, the COVID-19 impact is also included in the report.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_83262

TMR W.I.N Approach

TheW.I.N(Wholesome Competitive Insights.Important Trends.Noteworthy Regions.) Approach makes TMR one of the best research companies in the industry. This approach assures on-point information to the stakeholders and the CXOs.

Amniotic Products Market: Wholesome Competitive Insights

The amniotic products market has numerous players. The players formulate numerous strategies and methods to increase their consumer base. Research and development activities are one of them. The players invest in these activities for accelerating developments and finding insights. All these activities eventually add value to the growth trajectory of the amniotic products market.

Strategic collaborations are of immense importance for the amniotic products market. Mergers, acquisitions, joint ventures, and partnerships help in strengthening the influence of the players in the amniotic products market. All these aspects ultimately contribute to the growth of the amniotic products market.

Some well-established players in the amniotic products market are Integra LifeSciences, Lucina Biosciences, LifeCell International Pvt. Ltd., Orthoflix Medical Inc., and MTF Biologics.

Request for Analysis of COVID-19 Impact on Amniotic Products Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_83262

Amniotic Products Market: Important Trends

Growing Incidences of Burn Injuries to Invite Considerable Growth for Amniotic Products Market

Cases related to burn wounds and injuries have increased extensively over the years. The World Health Organization (WHO) states that nearly 180000 deaths are caused due to burns every year. The statistics by the WHO further highlight that more than 1000000 people are moderately or severely burnt every year. These statistics shed light on the need for treatment to decrease the effect of the wounds. As amniotic products are used for healing such wounds, the demand is expected to increase.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_83262

Implementation of Acts and Numerous Government Initiatives to Accelerate Regenerative Medicine Research brings Considerable Growth Opportunities

Many countries are focusing on boosting research in regenerative medicine. This aspect may have a great impact on the growth of the amniotic products market. Fast-track approvals for novel regenerative medicine products and other factors are also looked upon by introducing various acts and initiatives. Therefore, these factors will bring good growth prospects.

Pre Book Amniotic Products Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_83262&ltype=S

Amniotic Products Market: Noteworthy Regions

The amniotic products market in North America is estimated to observe a dominant stance during the forecast period. The introduction of laws like the 21stCentury Cures Act by the U.S. assures promising growth. Asia Pacific is expected to observe moderate growth during the forecast period.

More Trending Reports by Transparency Market Research:

Interventional Radiology Market According to Transparency Market Researchs latest report on the global Interventional Radiology market for the historical period20172018and forecast period20192027,high incidence of cancer, awareness programs by governments and NGOs, increase in maternal age and late pregnancies are projected to drive the global Interventional Radiology market during the forecast period

Inhalation and Nasal Spray Generic Drugs Market According to the report, the global inhalation and nasal spray generic drugs market was valued atUS$ 27.5 Bnin2018and is anticipated to expand at a CAGR of4.80%from2019to2027

Life Sciences BPO Market Gene therapies, intelligent drug discovery, telemedicine, and the likes are bringing about a change in the life sciences BPO market. Companies in the market for life sciences BPO are innovating through AI and machine learning (ML) for drug discovery.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Go here to see the original:
Amniotic Products Market: Growing incidence of burn injuries to drive the market - BioSpace

- Collaboration to Leverage Omega Epigenomic Controllers, a New Class of mRNA Therapeutics as Programmable Epigenetic Medicines, for Ocular Diseases by Targeting and Controlling Specific Ocular Disease Genes

Published: Oct. 14, 2021 at 6:00 AM CDT

CAMBRIDGE, Mass., Oct. 14, 2021 /PRNewswire/ --Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing platform, today announced a strategic research collaboration with researchers at the Stanford University School of Medicine to explore the therapeutic potential of Omega Epigenomic Controllers (OECs) to control ocular disease genes associated with inflammation or regeneration of ocular tissues.

Under the terms of the collaboration, Omega and members of the Ophthalmology Department of Stanford University School of Medicine will use the OMEGA Epigenomic Programming platform to discover and research novel ocular targets for potential futureOEC development candidates. Albert Wu, M.D., Ph.D., FACS, Associate Professor of Ophthalmology, will serve as principal investigator. Other contributors will include Jeffrey Goldberg, M.D., Ph.D., Professor and Chair of Ophthalmology, and Michael Kapiloff, M.D., Ph.D., Associate Professor (Research) of Ophthalmology.

"Through this research collaboration, we aim to expand the reach of our OMEGA platform within regenerative medicine, immunology, and inflammation with ocular disease targets," said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics. "We will continue exploration of the broad potential of our disruptive platform and OECs, our new class of mRNA therapeutics as programmable epigenetic medicines."

Detailed financial terms of the collaboration were not disclosed.

About Omega Therapeutics

Omega Therapeutics is a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming platform. The OMEGA platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth and differentiation to cell death. The OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega's engineered, modular, and programmable mRNA-encoded epigenetic medicines, Omega Epigenomic Controllers, target specific intervention points amongst the thousands of mapped and validated novel DNA-sequence-based epigenomic loci to durably tune single or multiple genes to treat and cure disease through Precision Genomic Control. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.

For more information, visitomegatherapeutics.com, or follow us onTwitterandLinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations for the collaboration with Stanford and our OMEGA Epigenomic ProgramingTMplatform.These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the novel technology on which our product candidates are based makes it difficult to predict the time and cost of preclinical and clinical development and subsequently obtaining regulatory approval, if at all; the substantial development and regulatory risks associated with epigenomic controller machines due to the novel and unprecedented nature of this new category of medicines; our limited operating history; the incurrence of significant losses and the fact that we expect to continue to incur significant additional losses for the foreseeable future; our need for substantial additional financing; our investments in research and development efforts that further enhance the OMEGA platform, and their impact on our results; uncertainty regarding preclinical development, especially for a new class of medicines such as epigenomic controllers; the fact that our product candidates may be associated with serious adverse events, undesirable side effects or have other properties that could halt their regulatory development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences; the impact of increased demand for the manufacture of mRNA and LNP based vaccines to treat COVID-19 on our development plans; difficulties manufacturing the novel technology on which our OEC candidates are based; our ability to adapt to rapid and significant technological change; our reliance on third parties for the manufacture of materials; our ability to successfully acquire and establish our own manufacturing facilities and infrastructure; our reliance on a limited number of suppliers for lipid excipients used in our product candidates; our ability to advance our product candidates to clinical development; and our ability to obtain, maintain, enforce and adequately protect our intellectual property rights.These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form10-Q for the period ended June 30, 2021and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Investor contact: Kevin Murphy/Brendan BurnsArgot Partners 212.600.1902 ArgotOmega@argotpartners.com

Media contact: David Rosen Argot Partners 212.600.1902 david.rosen@argotpartners.com

View original content to download multimedia:

SOURCE Omega Therapeutics

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.

Continue reading here:
Omega Therapeutics Announces Strategic Research Collaboration with Stanford University School of Medicine - KALB News

Gloria Clemons gives a COVID-19 vaccine to Navy veteran Perry Johnson at the Edward Hines, Jr. VA Hospital in Hines, Ill., in September. Scott Olson/Getty Images hide caption

Gloria Clemons gives a COVID-19 vaccine to Navy veteran Perry Johnson at the Edward Hines, Jr. VA Hospital in Hines, Ill., in September.

Conventional wisdom says that if you're vaccinated and you get a breakthrough infection with the coronavirus, you can transmit that infection to someone else and make that person sick.

But new evidence suggests that even though that may happen on occasion, breakthrough infections might not represent the threat to others that scientists originally thought.

Ross Kedl, an immunologist at the University of Colorado School of Medicine, will point out to anyone who cares to listen that basic immunology suggests the virus of a vaccinated person who gets infected will be different from the virus of an infected unvaccinated person.

That's because vaccinated people have already made antibodies to the coronavirus. Even if those antibodies don't prevent infection, they still "should be coating that virus with antibody and therefore helping prevent excessive downstream transmission," Kedl says. And a virus coated with antibodies won't be as infectious as a virus not coated in antibodies.

In Provincetown, Mass., this summer, a lot of vaccinated people got infected with the coronavirus, leading many to assume that this was an example of vaccinated people with breakthrough infections giving their infection to other vaccinated people.

Kedl isn't convinced.

"In all these cases where you have these big breakthrough infections, there's always unvaccinated people in the room," he says.

In a recent study from Israel of breakthrough infections among health care workers, the researchers report that in "all 37 case patients for whom data were available regarding the source of infection, the suspected source was an unvaccinated person."

It's hard to prove that an infected vaccinated person actually was responsible for transmitting their infection to someone else.

"I have seen no one report actually trying to trace whether or not the people who were vaccinated who got infected are downstream and certainly only could be downstream of another vaccinated person," Kedl says.

There's new laboratory evidence supporting Kedl's supposition. Initially, most vaccine experts predicted that mRNA vaccines like the ones made by Pfizer and Moderna that are injected into someone's arm muscle would generate only the kinds of antibodies that circulate throughout the body.

But that might not be the whole story.

"I think what was the big surprise here is that the mRNA vaccines are going beyond that," says Michal Caspi Tal, until recently an instructor at Stanford University's Institute for Stem Cell Biology and Regenerative Medicine and now a visiting scientist at the Massachusetts Institute of Technology.

What Tal has found is that in addition to the circulating antibodies, there was a surprisingly large amount of antibodies in mucosal membranes in the nose and mouth, two of the primary entry points for the coronavirus.

Immunologist Jennifer Gommerman of the University of Toronto found this as well.

"This is the first example where we can show that a local mucosal immune response is made, even though the person got the vaccine in an intramuscular delivery," Gommerman says.

If there are antibodies in the mucosal membranes, they would likely be coating any virus that got into the nose or throat. So any virus that was exhaled by a sneeze or a cough would likely be less infectious.

Gommerman says that until now, it seemed likely that a vaccine that was delivered directly to the mucosal tissue was the only way to generate antibodies in the nose or throat.

"Obviously a mucosal vaccination would be great too. But at least we're not sitting ducks," Gommerman says. "Otherwise everyone would be getting breakthrough infection."

Now, these studies by Gommerman and Tal have yet to undergo peer review, and some have already suggested that the antibodies they have described may not confer true mucosal immunity.

But there's other evidence that a vaccinated person's breakthrough infection may not transmit efficiently to others.

Marion Pepper, an immunologist at the University of Washington, says a recent study from the Netherlands looked at how well virus from vaccinated people could infect cells in the lab.

Pepper says the answer was not well.

"If you actually isolate virus from people who are getting a secondary infection after being vaccinated, that virus is less good at infecting cells," Pepper says. "It's not known why. Is it covered with an antibody? Maybe. Has it been hit by some other kind of immune mediators, cytokines, things like that? Maybe. Nobody really knows. But the virus does seem to be less viable coming from a vaccinated person."

More studies are emerging that suggest there's something different about the virus coming from a vaccinated person, something that may help prevent transmission.

Whatever it is, the University of Colorado's Kedl says it's one more reason that getting vaccinated is a good idea.

"Because you're going to be even more protected yourself. And you're going to be better off protecting other people."

Kedl says that's what you call a win-win situation.

See the rest here:
What the latest COVID research says about breakthrough cases and transmission : Shots - Health News - NPR

insightSLICE recently published a study titled Cell-Based Regenerative MedicineMarket Research Report.In this report, analysts have provided a detailed assessment of the Cell-Based Regenerative Medicine market with more than 100 market data tables, pie charts, graphs, and figures

This market study analyzes the market situation, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and barriers to entry, sales channels and the distributors.All statistical and numerical data, which are calculated with the most established tools such as SWOT analysis, are represented using graphs and tables for the best user experience and clear understanding.By using this Cell-Based Regenerative Medicine market report, general market conditions, existing trends and trends in this industry can be discovered.

Request a Free Sample Copy athttps://www.insightslice.com/request-sample/59

Highlights of the study report

COMPETITION ANALYSIS :

The competition model in the Cell-Based Regenerative Medicine market provides detailed information by the competitors.Detailed information includes company profile, company finances, revenue generated, market potential, R&D investments, new market plans, regional presence, strengths and weaknesses of the company. business.company, product versions, product width and width, and application benefits.

Manufacturers Covered By This Report:

Acelity (KCI Concepts), Cook Biotech Inc. Organogenesis Inc., Vericel Corporation, Osiris Therapeutics, Inc., and NuVasive, Inc., Medtronic , Stryker Corporation, Integra LifeSciences, and C.R. Bard.

Market segmentation :

The Cell-Based Regenerative Medicine market report has been separated on the basis of distinct categories such as product type, application, end-user, and region.Each segment is assessed on the basis of CAGR, share and growth potential.This segmental analysis will surely prove to be a useful tool for the readers, stakeholders and market players to get a complete picture of the Cell-Based Regenerative Medicine Market and its growth potential in the years to come.

Request a discount before purchasing this report @https://www.insightslice.com/request-discount/59

Regional analysis:

In addition to segmentation, the report also presents highly structured regional studies.The researchers comprehensive regional analysis highlights key regions and their major countries that account for a significant share of the Cell-Based Regenerative Medicine market revenue.The research helps to understand the market performance in various regions while also mentioning emerging regions which are growing at a significant CAGR.Here are the regions covered by this report

Europe(Germany, France, United Kingdom, Italy, Russia, Spain, Netherlands, Switzerland, Belgium)North America(United States, Canada)Asia-Pacific(China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Vietnam)Middle East and Africa(Turkey, Saudi Arabia, United Arab Emirates, South Africa, Israel, Egypt, Nigeria)Latin America(Brazil, Mexico, Argentina, Colombia, Chile, Peru).

The report answers questions such as:

Table of Contents: Global Cell-Based Regenerative Medicine Market Research Report 2021-2031

Chapter 1: Overview of the Cell-Based Regenerative Medicine MarketChapter 2: Economic Impact of the Cell-Based Regenerative Medicine MarketChapter 3: Competition by ManufacturerChapter 4: Production, Revenue (Value) by Region (2021-2031)Chapter 5: Supply (Production), Consumption, Export , Import by Regions (2021-2031)Chapter 6: Production, Revenue (Value), Price Trend by TypeChapter 7: Cell-Based Regenerative Medicine Market Analysis by ApplicationChapter 8: Cell-Based Regenerative Medicine Market by Manufacturing Cost AnalysisChapter 9: Chain Industry, Supply Strategy and Downstream BuyersChapter 10: Cell-Based Regenerative Medicine Marketing Strategy Analysis, Distributors / TradersChapter 11: Analysis of effect factors of the Cell-Based Regenerative Medicine marketChapter 12: Forecast of the Cell-Based Regenerative Medicine market (2021-2031)Chapter 13: Appendix

If you have any questions, ask our experts @https://www.insightslice.com/request-customization/59

Contact Information422 Larkfield Ctr # 1001, Santa Rosa,CA 95403-1408, USAinfo@insightslice.com+1 (707) 736 6633

Continue reading here:
Cell-Based Regenerative Medicine Market Analysis by SWOT, Investment, Future Growth and Major Key Players to 2031 Otterbein 360 - Otterbein 360

Coastal Spine

SCOTCH PLAINS, N.J. (PRWEB) October 15, 2021

NJ Top Docs has reviewed and approved Seth Scholl, DO, Mark A. Testaiuti, MD, Scott Jarmain, MD, Larry Deutsch, MD and Kamaldeep Singh Momi, MD of Coastal Spine for 2021.

Dr. Kam Momi is the founder of Coastal Spine. He has been Chief of the Spine Surgery Department for Jefferson South Jersey Hospitals since 2019. He is a board-certified orthopedic surgeon whose focus is exclusively on the neck and spine.

Dr. Deutsch is a board-certified orthopedic surgeon who has specialized in spine surgery for more than 30 years. He cofounded the Cooper Shriner spine fellowship program and has trained both orthopedic surgeons and neurosurgeons in spine surgery. Dr. Deutsch has been on the cutting edge of innovative procedures, which he has taught in both local and national settings.

Dr. Testaiuti is a board-certified neurosurgeon who specializes in spine care, complex spinal surgery, and minimally invasive spine surgery. He co-founded the Cooper Shriner spine fellowship program and has trained both orthopedic surgeons and neurosurgeons in spine surgery.

Dr. Jarmain is a specialist in physical medicine and rehabilitation, as well as pain management. He focuses on nonsurgical care of spine disorders. He performs spinal injections for diagnostic and therapeutic purposes throughout the entire spine. He also promotes Regenerative Medicine: where a patients own Platelet Rich Plasma, Stem Cells & Concentrated Bone Marrow Aspirate are utilized to treat chronic & acute injuries of joints, tendons, ligaments and the spine.

Dr. Scholl is a specialist in physical medicine and rehabilitation and deals solely with the nonsurgical treatment of neck, back and joint pain. He is the director of electrodiagnostics in which he performs all the pain-less EMGs and supervises the intraoperative monitoring uses during surgery.

Please visit the links below to learn more about these NJ Top Docs:

About Us

NJ Top Docs is a comprehensive, trusted and exclusive healthcare resource featuring reviewed and approved Top Doctors and Dentists in New Jersey online in an easy to use format. NJ Top Docs only reviews and approves providers based on merit after they have been extensively vetted.

NJ Top Docs is a division of USA Top Docs which allows patients to meet providers online before making their appointment.

For more information, please click here to contact us or visit http://www.NJTopDocs.com.

You can also follow us on Facebook, Twitter, & Instagram.

Share article on social media or email:

See the original post:
Five Coastal Spine Physicians Have Been Reviewed & Approved By NJ Top Docs For 2021 - PR Web

ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Brendan Smith as Chief Financial Officer, effective today. Mr. Smith brings more than 20 years of financial, operational and strategic leadership experience, including as CFO of Translate Bio. He succeeds Michael Tomsicek, who is retiring after four years of service to the Company. It is expected that Mr. Tomsicek will remain with the Company in an advisory role through the end of 2021 to help ensure a smooth transition.

I'm excited to welcome Brendan to our leadership team. His appointment comes at a time of significant opportunity and growth for CRISPR Therapeutics, said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics. Brendans business and financial expertise will be important in helping us continue to evolve the Company and realize our mission of transforming the lives of patients with serious diseases.

Dr. Kulkarni added: On behalf of the Board of Directors, shareholders, and our employees, I want to thank Mike for his contributions as CFO and for his dedicated service since joining CRISPR Therapeutics. Mike has been a valuable part of the continued development of the Company, and we wish him all the best in his retirement and look forward to working with him on a smooth transition.

Prior to CRISPR Therapeutics, Mr. Smith was the Chief Financial Officer & Corporate Strategy of Translate Bio, a leading mRNA company that was recently acquired by Sanofi for $3.2B. Mr. Smith is an accomplished executive with more than two decades of experience within high-growth biopharma environments where he made significant contributions in various operations and strategy positions. In these positions, Mr. Smith provided strategic financial leadership relating to long-term growth planning focused on operational efficiencies, building manufacturing and supply capabilities, and evaluation of business development opportunities and commercial planning assessments. Previously, as a Partner at Boston Consulting Group, Mr. Smith led integrated biopharma client engagements that included planning and executing on R&D strategy, operations, business development and deal diligence. Prior to that, Mr. Smith was VP, Head of Business Operations for Worldwide R&D at Pfizer, where he led financial and headcount planning across discovery and development operations. Prior, in his role as Executive Director, Head of Business Strategy and Operations for Biologics Pharmaceutical Sciences at Pfizer, Mr. Smith led manufacturing and financial operations for the companys global biologics process development organization. Mr. Smith received a B.S. in Biochemistry from Worcester Polytechnic Institute and an M.B.A. from Harvard Business School.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

CRISPR THERAPEUTICS word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:Susan Kim+1-617-307-7503susan.kim@crisprtx.com

Media Contact:Rachel Eides+1-617-315-4493rachel.eides@crisprtx.com

More:
CRISPR Therapeutics Announces Transition of Chief Financial Officer - BioSpace

DUBLIN--(BUSINESS WIRE)--The "Regenerative Medicine - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Regenerative Medicine Market to Reach $50.2 Billion by 2027

Amid the COVID-19 crisis, the global market for Regenerative Medicine estimated at US$12.2 Billion in the year 2020, is projected to reach a revised size of US$50.2 Billion by 2027, growing at a CAGR of 22.3% over the analysis period 2020-2027.

Cell Therapy, one of the segments analyzed in the report, is projected to record a 23.3% CAGR and reach US$25.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Gene Therapy segment is readjusted to a revised 21.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $3.7 Billion, While China is Forecast to Grow at 21.8% CAGR

The Regenerative Medicine market in the U.S. is estimated at US$3.7 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$8.7 Billion by the year 2027 trailing a CAGR of 21.8% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 20.1% and 18.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 15.6% CAGR.

Tissue Engineering Segment to Record 21.1% CAGR

In the global Tissue Engineering segment, USA, Canada, Japan, China and Europe will drive the 21% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.7 Billion in the year 2020 will reach a projected size of US$6.3 Billion by the close of the analysis period.

China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$5.9 Billion by the year 2027.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/6695iy

View original post here:
Global Regenerative Medicine Market Research Report 2021: Market to Surpass $50 Billion by 2027 - Cell Therapy Segment to Account for Half the Market...

By: QC Kinetix | 0Shares 26Reads

August 17, 2021 // Franchising.com // CHARLOTTE, N.C. - Inc. magazine today revealed that QC Kinetix is No. 62 on its annual Inc. 5000 list. The list represents a unique look at the most successful companies within the American economys most dynamic segmentits independent small businesses. The Charlotte, North Carolina-based company with a local presence, joins other well-known names like Intuit, Zappos, Under Armour, Microsoft, Patagonia, and many others who gained their first national exposure as honorees on the Inc. 5000.

We are honored and thrilled with our debut on the Inc. 5000 and especially with such a high ranking, said Justin Crowell, CEO of QC Kinetix. Our amazing growth really validates the science behind regenerative medicine and the work we are doing to bring our patients pain relief without surgery, pain pills, or downtime, so they can get back to living and doing the activities they enjoy pain-free.

Regenerative medicine develops treatment methods to regrow, repair, or replace damaged or diseased cells, organs, or tissues. This medical specialty uses the latest scientific research in the study of cells and tissue engineering to understand how the body can repair itself. For patients seeking relief from pain due to musculoskeletal injury, chronic joint pain, or hip, knee, or shoulder pain, regenerative procedures are the next frontier for treatment.

QC Kinetix differentiates itself by providing a high level of care and service to patients in a concierge setting that is unencumbered by insurance hassles. It is also the only regenerative medicine company offering a franchise opportunity to business owners who want to be part of this burgeoning medical specialty.

Chief Operating Officer and franchise industry veteran Scott Hoots credits the companys meteoric rise to a business model that combines purpose and profitability.

QC Kinetix is a brand with a purpose, which is to utilize the latest regenerative medicine treatments to enhance the quality of life for as many people as possible without the use of drugs or surgery. People are very motivated to use our cutting-edge treatments to help treat their pain and get back to living, and I think potential franchisees are highly interested in a franchise opportunity with a purpose-driven mission like ours, explained Hoots. There are many business opportunities out there today, but none that deliver a strong mix of financial performance plus a purpose-driven mission that has such a positive impact on peoples lives.

Not only have the companies on the 2021 Inc. 5000 been very competitive within their markets, but this years list also proved especially resilient and flexible given 2020s unprecedented challenges. Among the 5,000, the average median three-year growth rate soared to 543 percent, and median revenue reached $11.1 million. Together, those companies added more than 610,000 jobs over the past three years.

The 2021 Inc. 5000 list feels like one of the most important rosters of companies ever compiled, says Scott Omelianuk, editor-in-chief of Inc. Building one of the fastest-growing companies in America in any year is a remarkable achievement. Building one in the crisis weve lived through is just plain amazing. This kind of accomplishment comes with hard work, smart pivots, great leadership, and the help of a whole lot of people.

SOURCE QC Kinetix

###

Read more:
Local Regenerative Medicine Clinic Ranks No. 62 on the 2021 Inc. 5000 - Franchising.com